Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

Lung Cancer Video Library - Spanish Language: Video #34 Acquired Resistance to Targeted Therapies: Biology and Different Clinical Patterns

Resistencia adquirida a terapias dirigidas: biología y diferentes patrones clínicos

Acquired resistance to targeted therapies: biology and different clinical patterns

 Dr. Luis Raez, MD FACP FCCP

Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute,
Clinical Associate Professor of Medicine, Florida International University



Lamentablemente, a pesar que es muy emocionante ver como los pacientes que tienen las mutaciones de EGFR y las translocaciones ALK responden al inicio, sabemos que los tumores van a crear resistencia a estos agentes.

Usualmente es a los 10 o 12 meses que la mitad de los pacientes que están en estas terapias blanco, genera resistencia por muchas razones. Por ejemplo, en los receptores de EGFR, aparecen nuevas mutaciones como la mutación EGFRT790. En el caso de las translocaciones de ALK, también aparecen otras variantes nuevas que no están al comienzo que son variantes asociadas y documentadas para resistencia.

A pesar de que hay sensibilidad al comienzo, tenemos que estar alerta y monitorizando ya sea con radiografía o próximamente vamos a tener biopsias líquidas que vamos a poder estar monitorizando en la sangre para ver cuando empiezan la clonas resistentes a aparecer y en qué momento hay que empezar a cambiar la terapia.

Como ustedes saben felizmente, en el caso de la EGFR, cuando aparece resistencia tenemos otras terapias blanco como osimertinib. En el caso de las translocaciones ALK tenemos otras terapias blanco a parte de crisotinib que se usa al comienzo, tenemos ceritinib, alectinib y otros fármacos más que están por venir.





Unfortunately, despite the excitement of seeing patients with EGFR mutations and ALK translocations responding great to the treatment, we know that these tumors will create resistance to the therapy.

Usually at 10 or 12 months, half targeted therapy patients create resistance for many reasons. For example, in EGFR receptors, new mutations arise like EGFRT790. In ALK translocations, new variants appear that are associated and documented to resistance.

Despite there is sensitivity at the beginning, we have to be alert and monitoring with a radiography or in the near future with a liquid biopsy where we will be able to monitor blood and see when the resistant clones start to develop, and then change the therapy.

As you know, in EGFR when resistance starts, we have other new targeted therapies like osimertinib. In the ALK translocations, we have other targeted therapies besides crisotinib that is used in the beginning. We also have ceritinib, alectinib and other drugs that are coming.


Next Previous link

Previous PostNext Post

Related Content

Lung Cancer OncTalk 2023
At our live event, Lung Cancer OncTalk 2023, Dr. Yang, Das, and Dagogo-Jack discuss commonly used terms in treatment options for lung cancer, how oncologists determine the stage of lung cancer, and what that means for treatment, the importance of driver mutation in NSCLC treatment, the vast number of NSCLC trials, among other topics which involve lung cancer treatments. To watch the complete playlist click here.
Lung Cancer OncTalk 2023
At our live event, Lung Cancer OncTalk 2023, Dr. Jeff Yang, discusses different surgical procedures used to treat early-stage lung cancer and different approaches to removing cancerous tissue from the lung. 
Lung Cancer OncTalk 2023
At our live event, Lung Cancer OncTalk 2023, Dr. Millie Das, discusses different Studies and Trials for NSCLC. Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is the Chief of Oncology at the Palo Alto VA and is an active member of the VA National Lung Cancer Working Group and Lung Cancer Precision Oncology Program. Learn more about Dr. Das here.

Forum Discussions

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,


As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Recent Comments

Hi Amber, Welcome to Grace. …
By JanineT GRACE … on
Could you
By Maeve785 on
It sounds like you’re…
By Dr West on
Thank you Janine
By blaze100 on